Skip to content

Comparative Analysis of Analgesic Efficacy: by Single Shot Intrathecal Analgesia (SSSA) in Normal Labor

Comparative Analysis of Analgesic Efficacy and Maternal Satisfaction: Single Shot Intrathecal Bupivacaine With Fentanyl Versus Bupivacaine With Dexmedetomidine in Normal Labor, Randomized Control Clinical Trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06823349
Acronym
SSSA
Enrollment
90
Registered
2025-02-12
Start date
2025-02-01
Completion date
2025-07-31
Last updated
2025-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Normal Labor, Vaginal Delivery

Keywords

painless normal labor, Single shot spinal analgesia in vaginal delivery

Brief summary

the goal of this randomized control trial is to compare the effect of adding fentanyl v.s dexmedetomidine to bupivacaine in single shot spinal analgesia in achievement of analgesia by decreasing visual analogue scale, onset and increasing duration of analgesia in normal labor.

Detailed description

on arrival to the operating room, the demographic and baseline data will be collected, which include sections about age, height, weight, primigravida or multigravida, cervical dilation at the time of performing labor analgesia, fetus presentation, presence of rupture of membrane, baseline pain scores will be assessed using a 10-cm VAS (0 = no pain and 10 = worst imaginable pain) before SSSA. Intravenous access will be achieved in all patients loading will be undertaken using 500 ml Ringer's solution, baseline values of pulse rate (PR), respiratory rate (RR), hemoglobin oxygen saturation (SpO2), and arterial blood pressure (ABP) will be recorded. SSSA will be performed with the parturient in the sitting position under complete aseptic precautions at the L3-L4 level using a 25-gauge spinal needles. The correct positioning of the needle tip in the intrathecal space will be confirmed by the observation of a free flow of cerebrospinal fluid, and then the prefilled study drug will be injected intrathecally which is 2.5 mg bupivacaine plus 25 mic fentanyl or 5 mic dexmedetomidine or 0.5 ml saline according to different groups. parturient will then turn to the supine position, and a wedge will be placed under the right buttocks to prevent aortocaval compression. VAS will be evaluated every 5 min for the first 30 min, followed by every 20 min for 3 hours then every 30 min for next 3 hours. If VAS 8 or more the instigators will give the patient 50 mg intramuscular pethidine. Maternal blood pressure, heart rate, respiratory rate, and oxygen saturation will be measured and recorded noninvasively every 5 min for the first half hour, followed by every 20 min for 3 hours, then every 1 h for next 3 hours. the investigators will give 5 mg ephedrine if there is hypotension ( decrease in ABP more than 25% of the baseline ABP) and .5 mg atropine if there is bradycardia (HR less than 50 beats per minute). Side effects such as hypotension, nausea, vomiting, bradycardia, shivering, pruritus, and tachycardia will be recorded. The first- and fifth-minute Apgar scores will also be recorded. The onset, duration of analgesia, and obstetric and neonatal outcomes will be compared.

Interventions

DRUGDexmedetomidine

5 mic dexmedetomidine will be given intrathecally added to 2.5 mg bupivacaine

DRUGfentanyl

25 mic of fentanyl will be given intrathecally added to 2.5 mg bupivacaine

DRUGSaline 0.9%

0.5 ml of saline 0.9% will be given intrathecally added to 2.5 mg of bupivacaine

Sponsors

Jehan George Sadek
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
Yes

Inclusion criteria

* ASA I-II. * Uncomplicated pregnancy. * At term & singleton fetus. * Cervical dilatation \> 5cm * Cephalic presentations

Exclusion criteria

* Patient refusal. * Bleeding disorders and patients on anticoagulant drugs. * Infection at site of injection. * Spine deformity. * Allergy to any of study medications.

Design outcomes

Primary

MeasureTime frameDescription
the duration and onset of analgesia.baseline, pre intervention and after intervention for an average 6 hoursonset of analgesia will be determined as time taken (in minutes) from the administration of intrathecal drug to the patient reporting effective pain relief (e.g. vas score reduction) duration of analgesia will be determined as time ( in minutes) from onset of analgesia until the patient require additional analgesia or reports significant pain (e.g. VAS score above a threshold).
the change in visual analogue scale (VAS) of the labor pain.baseline, pre intervention and after intervention an average 6 hourschange in visual analogue score (VAS) as it is score for measuring pain intensity consisting of 0 to 10 cm line with endpoints labeled as 0 is no pain and 10 is the worst pain and will be evaluated every 5 min for the first 30 min, followed by every 20 min for 3 hours then every 30 min for next 3 hours

Secondary

MeasureTime frameDescription
change in maternal hemodynamics as heart ratebaseline, pre intervention and after intervention for an average 6 hoursheart rate will be measured and recorded noninvasively every 5 minutes for the first half hour, followed by every 20 minutes for 3 hours, then every 1 hour for next 3 hours. a bradycardia will be defined as (HR less than 50 beats per minute).
maternal satisfaction assessed using a satisfaction questionnaire.At delivery/birthit is a questionnaire that has been made according to 5 scale questionnaire as 1-is very dissatisfied 2- dissatisfied 3- neutral 4- satisfied 5- very satisfied.
Apgar score at 1 and 5 minutes.will be recorded 1 minute after delivery and 5 minutes after delivery.score range 0-10, assessing skin color, heart rate, reflexes, muscle tone, respiratory effort and rate. total score range from 0 to 10. a score of 7 or above indicate good health, while a lower score may require medical attention.
change in maternal hemodynamics as respiratory rate.baseline, pre intervention and after intervention for an average 6 hours.respiratory rate will be measured and recorded noninvasively every 5 minutes for the first half hour, followed by every 20 minutes for 3 hours, then every 1 hour for next 3 hours. Bradypnea will be defined as respiratory rate below 12 cycle / minute.
change in maternal hemodynamics as blood pressure.baseline, pre intervention and after intervention for an average 6 hoursMaternal blood pressure will be measured and recorded noninvasively every 5 minutes for the first half hour, followed by every 20 minutes for 3 hours, then every 1 hour for next 3 hours. a hypotension will be defined as ( decrease in mean ABP more than 25% of the baseline mean ABP).

Countries

Egypt

Contacts

Primary ContactJehan G Younan, resident doctor.
jehan.younan1995@gmail.com+20 01222333194

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026